133 related articles for article (PubMed ID: 24843604)
1. Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic mice.
Tsuji T; Yoshida Y; Fujita T; Kohno T
J Diabetes Investig; 2012 Oct; 3(5):441-8. PubMed ID: 24843604
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once-daily injection of insulin glargine in non-obese diabetic mice.
Tsuji T; Inoue M; Yoshida Y; Fujita T; Kaino Y; Kohno T
J Diabetes Investig; 2012 Mar; 3(2):132-7. PubMed ID: 24843556
[TBL] [Abstract][Full Text] [Related]
3. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice.
Tsuji T; Yoshida Y; Iwatsuki R; Inoue M; Fujita T; Kohno T
Biol Pharm Bull; 2012; 35(8):1314-9. PubMed ID: 22863931
[TBL] [Abstract][Full Text] [Related]
5. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
Maki T; Gottschalk R; Ogawa N; Monaco AP
Transplantation; 2005 May; 79(9):1051-5. PubMed ID: 15880042
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2009 Mar; 58(3):641-51. PubMed ID: 19073764
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulator FTY720 improves glucose homeostasis and diabetic complications by rejuvenation of β-cell function in nonhuman primate model of diabetes.
Wang YJ; Wang X; An A; Zang M; Xu L; Gong K; Song W; Li Q; Lu X; Xiao YF; Yu G; Ma ZA
Fundam Clin Pharmacol; 2022 Aug; 36(4):699-711. PubMed ID: 35064580
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 (fingolimod) in combination with betamethasone ointment in NC/Nga mice].
Tsuji T; Yoshida Y; Fujita T; Kohno T
Arerugi; 2012 Jul; 61(7):948-58. PubMed ID: 23007332
[TBL] [Abstract][Full Text] [Related]
10. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
Eitah HE; Maklad YA; Abdelkader NF; Gamal El Din AA; Badawi MA; Kenawy SA
Toxicol Appl Pharmacol; 2019 Feb; 365():30-40. PubMed ID: 30576699
[TBL] [Abstract][Full Text] [Related]
11. Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor.
Ansarullah ; Lu Y; Holstein M; DeRuyter B; Rabinovitch A; Guo Z
PLoS One; 2013; 8(1):e53345. PubMed ID: 23382843
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
[TBL] [Abstract][Full Text] [Related]
13. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
Penaranda C; Tang Q; Ruddle NH; Bluestone JA
Diabetes; 2010 Jun; 59(6):1461-8. PubMed ID: 20299465
[TBL] [Abstract][Full Text] [Related]
14. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Cabrera SM; Colvin SC; Tersey SA; Maier B; Nadler JL; Mirmira RG
Clin Exp Immunol; 2013 Jun; 172(3):375-82. PubMed ID: 23600825
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
[TBL] [Abstract][Full Text] [Related]
16. FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice.
Moon H; Chon J; Joo J; Kim D; In J; Lee H; Park J; Choi J
Diabetes Metab Res Rev; 2013 Jan; 29(1):19-24. PubMed ID: 22936676
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
20. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
